TOPLINE: In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly increase the risk for falls, and combined use with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) further heightened this risk, emphasizing the need for careful management and support for patients receiving these therapies…
Leave a Comment Leave a Comment
